EMA starts evaluation of Moderna's booster application

Moderna has applied for the European health authority's approval for the use of its Covid-19 vaccine, Spikevax, as a booster dose in re-vaccination schemes.

Photo: David W Cerny/Reuters/Ritzau Scanpix

The European Medicines Agency (EMA) has begun its assessment of data from US-based Moderna, which has applied for the approval of its Spikevax in use as a Covid-19 booster vaccine, the EMA reports in a press release.

The hope is to use Spikevax for the re-vaccination of people aged 12 and over six months after they have received the second vaccine shot, with the aim of boosting the vaccine's effectiveness by prolonging a high Covid-19 protection.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs